Forecast

The analysts' average price target is +23,17€ (−0,69%). The median is +23,17€ (−0,69%).

Buy	11
Hold	2
Sell	0

News Go to news feed

Chiesi completes acquisition of KalVista for $27 per share

Chiesi has completed the acquisition of KalVista, acquiring all outstanding shares for $27.00 per share in cash after approximately 77.8% of the shares were tendered. KalVista becomes a wholly owned subsidiary and is valued at $1.44 billion; trading of the common shares was suspended on Nasdaq. Chiesi acquires the oral HAE treatment EKTERLY (Sebetralstat) and is integrating KalVista into its rare diseases unit, while approvals in additional markets and pediatric studies are underway. » More on de.investing.com
KalVista chief development officer sells 33,800 shares after exercising options

Christopher Yea exercised 33,800 options and immediately sold the resulting KalVista shares for about $905,000 at a weighted average price of $26.78 on May 27, 2026, leaving him with 229,918 shares valued at roughly $6.16 million. The sale is Yea's second open-market disposal and did not increase his long-term holdings since the shares were sourced from vested options. The report notes a pending buyout offer from Chiesi Group at $27 per share expected to close in Q3 2026 and summarizes KalVista's commercial focus on oral plasma kallikrein inhibitors and recent Ekterly sales. » More on finance.yahoo.com
KalVista reaches 52-week high after takeover announcement

KalVista’s stock rose to a 52-week high of $26.85, driven by the announcement of an acquisition by the Chiesi Group for about $1.9 billion. Chiesi is offering $27.00 per share, a 36% premium to the volume-weighted 30-day average; the acquisition was unanimously approved by both boards and is expected to close in Q3 2026. After the news, analysts adjusted their ratings, mostly downgrading the stock from “Buy” to “Neutral/Hold” and setting the price target at the offer price. » More on de.investing.com

Financials

In the last quarter, KalVista Pharma had revenue of 51.77m€ and net profit of −4.64m€

(EUR)	Mar 2026	YoY
Revenue	+51.77m	-
Gross profit	+48.33m	444,44%
Net profit	−4.64m	89,94%
EBITDA	−2.80m	93,65%

Fundamentals

Metric	Value
Market capitalization	+1.23b€
Number of shares	53.24m
52-week high/low	+23,17€ - +8,44€
Dividends	No
Beta	-0,29
P/E ratio	−8,36
PEG ratio	−0,56
P/B ratio	−503,31
P/S ratio	+12,40

Company profile

KalVista Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen in der klinischen Phase, das niedermolekulare Proteasehemmer für Krankheiten mit ungedecktem Bedarf entdeckt, entwickelt und vermarktet. Das Produktportfolio des Unternehmens umfasst niedermolekulare Plasmakallikrein-Inhibitoren zur Behandlung des hereditären Angioödems (HAE) und des diabetischen Makulaödems (DME) sowie orale Plasmakallikrein-Inhibitoren. Zu den Produkten des Unternehmens gehören KVD001, ein Plasmakallikrein-Inhibitor, der eine klinische Phase-II-Studie zur Behandlung des DME abgeschlossen hat, KVD900, das eine klinische Phase-II-Studie für eine orale On-Demand-Therapie bei akuten HAE-Attacken abgeschlossen hat, und KVD824, ein oraler Produktkandidat zur Behandlung von HAE. Der Hauptsitz des Unternehmens befindet sich in Cambridge, Massachusetts.